← Leaderboards
Peter M Grace
University Of Tx Md Anderson Can Ctr
$7,419,176
Attributed
$10,553,293
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,553,293 · 5
By mechanism
R01$3,434,343 · 2
RF1$3,224,916 · 1
UG3$2,408,109 · 1
UH3$1,485,925 · 1
Top collaborators
- Andrew John Shepherd4 shared
- Andrew Abell2 shared
- Cobi J Heijnen2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Cobi J Heijnen$4,217,788
- Andrew John Shepherd$7,386,853
- Katy Rezvani$10,195,970
- Michele M Mulholland$2,350,447
- Shao-Rui Chen$3,356,636
Others in their field
Other Emerging Leaders on “Innovation”
- Klaus Romero · Critical Path Institute$86,053,372
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$69,953,681
- Tony Moody · Duke University$65,625,959
- Matthew Johnson · Duke University$60,590,296
Research focus
InnovationPublic HealthPainPeripheralSolidNeuroimmuneCellsPainful NeuropathyNational Institute Of Neurological Disorders And StrokeTherapeutic TargetMissionPharmaceutical PreparationsPathway InteractionsBiochemicalReflex ActionPain BehaviorSiteSide EffectMediatingPre-ClinicalBiologicalFda ApprovedAdverse EffectsToxic Effect
Grant awards (11)
Regulation of Peripheral Neuropathic Pain by B Cells$484,813
R01 · FY2025 · NS · contact PI
Development of Pathology-activated Drugs for Treatment of Neuropathic Pain$1,485,925
UH3 · FY2024 · NS · contact PI
Regulation of Peripheral Neuropathic Pain by B Cells$575,329
R01 · FY2024 · NS · contact PI
Regulation of Peripheral Neuropathic Pain by B Cells$626,592
R01 · FY2023 · NS · contact PI
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$359,431
R01 · FY2023 · CA · contact PI
Development of Pathology-activated Drugs for Treatment of Neuropathic Pain$2,408,109
UG3 · FY2022 · NS · contact PI
Regulation of Peripheral Neuropathic Pain by B Cells$621,493
R01 · FY2022 · NS · contact PI
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$1
R01 · FY2022 · CA · contact PI
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$366,766
R01 · FY2021 · CA · contact PI
Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain$3,224,916
RF1 · FY2019 · NS · contact PI
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$399,918
R01 · FY2019 · CA · contact PI